Grifols, S.A Net Cash Flow 2012-2025 | GRFS

Grifols, S.A net cash flow for the twelve months ending June 30, 2025 was $0.961B, a 130.25% decline year-over-year.

  • Grifols, S.A annual net cash flow for 2024 was $0.487B, a 2545.98% decline from 2023.
  • Grifols, S.A annual net cash flow for 2023 was $-0.02B, a 99.11% decline from 2022.
  • Grifols, S.A annual net cash flow for 2022 was $-2.242B, a 190.4% decline from 2021.

Grifols, S.A Net Cash Flow 2012-2025 | GRFS

  • Grifols, S.A annual net cash flow for 2024 was $0.487B, a 2545.98% decline from 2023.
  • Grifols, S.A annual net cash flow for 2023 was $-0.02B, a 99.11% decline from 2022.
  • Grifols, S.A annual net cash flow for 2022 was $-2.242B, a 190.4% decline from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$69.6B
Zoetis (ZTS)$67.5B
Daiichi Sankyo, - (DSNKY)$48.8B
Takeda Pharmaceutical (TAK)$48.2B
BeOne Medicines - (ONC)$35B
Sandoz Group AG (SDZNY)$26.3B
Summit Therapeutics (SMMT)$19.5B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$14.2B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11.2B
IPSEN (IPSEY)$10.6B
Eisai (ESAIY)$9.2B
Madrigal Pharmaceuticals (MDGL)$8.7B
Corcept Therapeutics (CORT)$7.6B
Ionis Pharmaceuticals (IONS)$6.9B
Stevanato Group S.p.A (STVN)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Ono Pharmaceutical (OPHLF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
NewAmsterdam Pharma (NAMS)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.8B
Hypermarcas (HYPMY)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.4B
Ocular Therapeutix (OCUL)$2.1B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B